Safety and feasibility of levosimendan administration in takotsubo cardiomyopathy: A case series

Cardiovascular Therapeutics

Volumn 31, Issue 6, 2013, Pages e133-e137

  Santoro, Francesco ^a   Ieva, Riccardo ^a   Ferraretti, Armando ^a   Ienco, Vincenzo ^a   Carpagnano, Giuseppe ^a   Lodispoto, Michele ^a   Di Biase, Luigi ^a   Di Biase, Matteo ^a   Brunetti, Natale Daniele ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Heart failure; Levosimendan; Safety; Takotsubo cardiomyopathy

Indexed keywords

LEVOSIMENDAN; TROPONIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; HYPOVOLEMIA; INFUSION RATE; LENGTH OF STAY; LUNG EDEMA; MALE; PHYSICAL STRESS; PNEUMOTHORAX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SIDE EFFECT; SINUS TACHYCARDIA; ST SEGMENT ELEVATION; SURGICAL STRESS; TAKOTSUBO CARDIOMYOPATHY; THORAX PAIN; TORSADE DES POINTES; URINARY SEPSIS;

HEART FAILURE; LEVOSIMENDAN; SAFETY; TAKOTSUBO CARDIOMYOPATHY;

AGED; AGED, 80 AND OVER; CALCIUM; FEMALE; HUMANS; HYDRAZONES; LENGTH OF STAY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDAZINES; TAKOTSUBO CARDIOMYOPATHY;

EID: 84888316334     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12047     Document Type: Article

References (29)

1. Donohue D, Movahed MR. Clinical characteristics, demographics and prognosis of 78 transient left ventricular apical ballooning syndrome. Heart Fail Rev 2005;10:79311-79316.
2. Brunetti ND, Ieva R, Rossi G, et al. Ventricular outflow tract obstruction, systolic anterior motion and acute mitral regurgitation in Tako-Tsubo syndrome. Int J Cardiol 2008;127:e152-e157.
3. Ieva R, Santoro F, Ferraretti A, Spennati G, De Gennaro L, Di Biase M, Brunetti ND. Hyper-acute precipitating mechanism of Tako-Tsubo cardiomyopathy: in the beginning was basal hyperkinesis? Int J Cardiol 2013;167:e55-e57.
4. Brunetti ND, Ferraretti A, Scarcia M, et al. Ultra-fast Tako-Tsubo cardiomyopathy after local anesthesia for eye surgery: are we missing the submerged bottom of the iceberg? Int J Cardiol 2013;167:e137-e139.
5. Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005;352:539-548.
6. Gianni M, Dentali F, Grandi AM, Sumner G, Hiralal R, Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: a systemic review. Eur Heart J 2006;27:1523-1529.
7. Sharkey SW, Lesser JR, Zenivich AG, Maron MS, Lindberg J, Longe TF, Maron BJ. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation 2005;111:472-479.
8. Arias AM, Oberti PF, Pizarro R, Falconi ML, de Arenaza DP, Zeffiro S, Cagide AM. Dobutamine-precipitated Takotsubo cardiomyopathy mimicking acute myocardial infarction: a multimodality image approach. Circulation 2011;124:e312-e315.
9. Paur H, Wright PT, Sikkel MB, et al. High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation 2012;126:697-706.
10. Lehtonen L. Levosimendan: a promising agent for the treatment of hospitalized patients with decompensated heart failure. Curr Cardiol Rep 2000;2:233-243.
11. Madhavan M, Rihal CS, Lerman A, Prasad A. Acute heart failure in apical ballooning syndrome (TakoTsubo/stress cardiomyopathy): clinical correlates and Mayo Clinic risk score. J Am Coll Cardiol 2011;57:1400-1401.
12. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (TakoTsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J 2008;155:408-417.
13. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
14. Santoro F, Correale M, Ieva R, Caiaffa MF, Pappalardo I, Di Biase M, Brunetti ND. Tako-Tsubo cardiomyopathy following an allergic asthma attack after cephalosporin administration. Int J Cardiol 2012;159:e20-e21.
15. Brunetti ND, Ieva R, Correale M, et al. Combined exogenous and endogenous catecholamine release associated with Tako-Tsubo like syndrome in a patient with atrio-ventricular block undergoing pace-maker implantation. Acute Card Care 2011;13:112-114.
16. Padayachee L. Levosimendan: the inotrope of choice in cardiogenic shock secondary to takotsubo cardiomyopathy? Heart Lung Circ 2007;16(Suppl 3):S65-S70.
17. De Santis V, Vitale D, Tritapepe L, Greco C, Pietropaoli P. Use of levosimendan for cardiogenic shock in a patient with the apical ballooning syndrome. Ann Intern Med 2008;149:365-367.
18. Antonini M, Stazi GV, Cirasa MT, Garotto G, Frustaci A. Efficacy of levosimendan in Takotsubo-related cardiogenic shock. Acta Anaesthesiol Scand 2010;54:119-120.
19. Karvouniaris M, Papanikolaou J, Makris D, Zakynthinos E. Sepsis-associated takotsubo cardiomyopathy can be reversed with levosimendan. Am J Emerg Med 2012;30:832. e5-7.
20. Boden H, Ahmed TA, Velders MA, et al. Peak and fixed-time high-sensitive troponin for prediction of infarct size, impaired left ventricular function, and adverse outcomes in patients with first ST-segment elevation myocardial infarction receiving percutaneous coronary intervention. Am J Cardiol 2013;00:0-0. Feb 25. [Epub ahead of print]
21. De Gennaro L, Brunetti ND, Cuculo A, Pellegrino PL, Izzo P, Roma F, Di Biase M. Increased troponin levels in nonischemic cardiac conditions and noncardiac diseases. J Interv Cardiol 2008;21:129-139.
22. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novelcalcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-1866.
23. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006;104:556-569.
24. Ellger BM, Zahn PK, Van Aken HK, Schmidt C, Brussel T. Levosimendan: a promising treatment for myocardial stunning? Anaesthesia 2006;61:61-63.
25. Husebye T, Eritsland J, Müller C, et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail 2013;15:565-572.
26. Aidonidis G, Kanonidis I, Koutsimanis V, Neumann T, Erbel R, Sakadamis G. Efficiency and safety of prolonged levosimendan infusion in patients with acute heart failure. Cardiol Res Pract 2011;2011:342302.
27. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
28. Lehtonen L, Põder P. The utility of levosimendan in the treatment of heart failure. Ann Med 2007;39:2-17.
29. Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 2006;98:1641-1645.